Skip to content

Study · In vitro (cells) · 2009

4 results

Growth hormone-releasing peptide 6 protection of hypothalamic neurons from glutamate excitotoxicity is caspase independent and not mediated by insulin-like growth factor I.

Delgado-Rubín A, Chowen JA, Argente J, Frago LM

The European journal of neuroscience21 May 2009Cited by 17 (Europe PMC)

PMID19490089 (opens in a new tab)DOI10.1111/j.1460-9568.2009.06770.x (opens in a new tab)PepBankPUB-19490089
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In RCA-6 hypothalamic neurons, GHRP‑6 partially reversed glutamate-induced cell death.

    In plain wordsIn cells, GHRP‑6 partly protected nerve cells from death caused by glutamate.

    Peptide
    GHRP-6
    Outcome
    DecreaseGlutamate-induced cell death
    Study

    n: not reported in source

    RCA-6 fetal hypothalamic neuronal cell line, glutamate-induced apoptosis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Growth hormone-releasing peptide 6 partially reversed glutamate-induced cell death
    1 context sentence
    Summary · context
    Thus, the aim of this study was to investigate whether the administration of growth hormone-releasing peptide 6 and insulin-like growth factor I attenuates monosodium glutamate-induced apoptosis in RCA-6 neurons and the mechanisms involved.
  2. 02LabIn vitro (cells)Mechanism

    In RCA-6 hypothalamic neurons, GHRP‑6 did not reverse glutamate-induced caspase activation.

    In plain wordsIn cells, GHRP‑6 did not stop glutamate from switching on caspases, which are cell-death enzymes.

    Peptide
    GHRP-6
    Outcome
    No significant changeGlutamate-induced caspase activation
    Study

    n: not reported in source

    RCA-6 fetal hypothalamic neuronal cell line, glutamate-induced apoptosis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Growth hormone-releasing peptide 6 partially reversed glutamate-induced cell death but not the activation of caspases, suggesting blockage of the caspase-independent cell death pathway, which included interference with the translocation of apoptosis-inducing factor to the nucleus associated with the induction of Bcl-2.
    1 context sentence
    Summary · context
    Thus, the aim of this study was to investigate whether the administration of growth hormone-releasing peptide 6 and insulin-like growth factor I attenuates monosodium glutamate-induced apoptosis in RCA-6 neurons and the mechanisms involved.
  3. 03LabIn vitro (cells)Mechanism

    In RCA-6 hypothalamic neurons, the partial protection by GHRP‑6 against glutamate was suggested to involve interference with translocation of apoptosis-inducing factor to the nucleus.

    In plain wordsIn cells, GHRP‑6's partial protection from glutamate may involve less movement of a cell-death factor into the nucleus.

    Peptide
    GHRP-6
    Outcome
    DecreaseTranslocation of apoptosis-inducing factor to the nucleus
    Study

    n: not reported in source

    RCA-6 fetal hypothalamic neuronal cell line, glutamate-induced apoptosis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Growth hormone-releasing peptide 6 partially reversed glutamate-induced cell death but not the activation of caspases, suggesting blockage of the caspase-independent cell death pathway, which included interference with the translocation of apoptosis-inducing factor to the nucleus associated with the induction of Bcl-2.
    1 context sentence
    Summary · context
    Thus, the aim of this study was to investigate whether the administration of growth hormone-releasing peptide 6 and insulin-like growth factor I attenuates monosodium glutamate-induced apoptosis in RCA-6 neurons and the mechanisms involved.
  4. 04LabIn vitro (cells)Mechanism

    In RCA-6 hypothalamic neurons, the partial protection by GHRP‑6 against glutamate was associated with induction of Bcl-2.

    In plain wordsIn cells, GHRP‑6's partial protection from glutamate was linked to Bcl-2, a protein that protects cells from death.

    Peptide
    GHRP-6
    Outcome
    IncreaseBcl-2 induction
    Study

    n: not reported in source

    RCA-6 fetal hypothalamic neuronal cell line, glutamate-induced apoptosis
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Growth hormone-releasing peptide 6 partially reversed glutamate-induced cell death but not the activation of caspases, suggesting blockage of the caspase-independent cell death pathway, which included interference with the translocation of apoptosis-inducing factor to the nucleus associated with the induction of Bcl-2.
    1 context sentence
    Summary · context
    Thus, the aim of this study was to investigate whether the administration of growth hormone-releasing peptide 6 and insulin-like growth factor I attenuates monosodium glutamate-induced apoptosis in RCA-6 neurons and the mechanisms involved.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.